Wen Ping, Song Dan, Ye Hong, Wu Xiaochun, Jiang Lei, Tang Bing, Zhou Yang, Fang Li, Cao Hongdi, He Weichun, Yang Yafang, Dai Chunsun, Yang Junwei
Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Department of Nephrology, Affiliated Wuxi Hospital, Nanjing Medical University, Wuxi, China.
PLoS One. 2014 Oct 14;9(10):e103079. doi: 10.1371/journal.pone.0103079. eCollection 2014.
MicroRNAs (miRNAs) are small ribonucleotides regulating gene expression. MicroRNAs are present in the blood in a remarkably stable form and have emerged as potential diagnostic markers in patients with cardiovascular disease. Our study aimed to assess circulating miR-133a levels in MHD patients and the relation of miR-133a to cardiac hypertrophy.
We profiled miRNAs using RNA isolated from the plasma of participants. The results were validated in 64 MHD patients and 18 healthy controls.
Levels of plasma miR-133a decreased in MHD patients with LVH compared with those in healthy controls. Plasma miR-133a concentrations were negatively correlated with LVMI and IVS. After single hemodialytic treatment, plasma miR-133a levels remained unchanged. Cardiac Troponin I and T were not associated with LVMI and IVS.
Our observations supplied the possibility that circulating miR-133a could be a surrogate biomarker of cardiac hypertrophy in MHD patients.
微小RNA（miRNA）是一类调节基因表达的小核糖核苷酸。微小RNA以一种非常稳定的形式存在于血液中，并已成为心血管疾病患者潜在的诊断标志物。我们的研究旨在评估维持性血液透析（MHD）患者循环中miR-133a的水平以及miR-133a与心肌肥厚的关系。
我们使用从参与者血浆中分离的RNA对微小RNA进行分析。结果在64例MHD患者和18例健康对照中得到验证。
与健康对照相比，患有左心室肥厚（LVH）的MHD患者血浆miR-133a水平降低。血浆miR-133a浓度与左心室质量指数（LVMI）和室间隔厚度（IVS）呈负相关。单次血液透析治疗后，血浆miR-133a水平保持不变。心肌肌钙蛋白I和T与LVMI和IVS无关。
我们的观察结果提示，循环miR-133a有可能成为MHD患者心肌肥厚的替代生物标志物。
